A new day in preventing meningococcal disease: Sizing up the available vaccines
The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.
Recent Videos
Related Content
Pediatric cancer survivors and cardiovascular toxicity, disease risk
March 21st 2025Article
Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.
